PYC THERAPEUTICS LIMITED — AGM Information 2018

Nov 15, 2018

Phylogica

AGM Presentation November 2018

We are solving one of the most important challenges in pharmacology

Delivering large molecules inside cells to reach 'undruggable' targets is one of the biggest challenges in modern drug development…

…Where success is commensurately rewarded (even in early-stage companies)

Pre-clinical company SQZ Biotechnologies recently completed a deal with Roche involving:

• US$125m up-front/near-term;
• US$250m clinical, regulatory and sales milestones per product; and
• US$1bn developmental milestones

Cell Penetrating Peptides (CPPs) sit on the cusp of clinical validation

Sarepta have taken promising preclinical results driven by Cell Penetrating Peptides (CPPs)…

mdx mice at 7 weeks of age were treated with a single IV dose of PPMO at 10, 20, 40, or 80 mg/kg and analysed at 30 days post-injection (N=6 mice per group)

…Into the clinic

• i) CPP-PMO (PPMO) is now in Phase 1 trials
• ii) multiple follow on CPP-PMO programs are scheduled for IND in 2019

"If the [CP]PPMO tech works, it will not only be fantastic for kids with DMD, but it also allows us to move beyond DMD and into other therapeutic areas"

Sarepta CEO

Efficiency of delivery remains the rate-limiting step in the field

Phylogica has a major competitive advantage in CPPs

We have the richest and most structurally diverse source library for Cell Penetrating Peptides (CPPs)…

Comparison of efficiency of Phylogica's CPPs (orange) with 'conventional' CPPs (blue)

…And we are translating this advantage from the libraries into our 'platform'

The 3D protein landscape - One of the many dimensions of drug-like properties we are optimising for using advanced analytics to tailor a CPP for particular cargoes and target tissues

Our CPPs deliver more cargo inside cells than competitor CPPs

We have a clear path to translate our differentiation into 'a molecule'

We will soon realise a major milestone in validating our platform

We will achieve this objective with an Anti-Sense Oligonucleotide (ASO) cargo

ASOs have weak intrinsic cell penetrating properties

"The great thing about this PMO technology is that it's precise and safe. It gets down to the RNA level and does exon-skipping… But it does have a limitation—the PMOs are neutrally charged, meaning they don't get into cells as efficiently as we would like"

ASOs are an emerging class of therapeutics

"Oligonucleotide therapeutics have the potential to change the way disease is treated due to their ability to modulate gene expression of any therapeutic target in a highly specific and potent manner"

Scientific Journal

Sarepta CEO

In 2019 we will…

• 1. Deliver the data that matters therapeutic in vivo validation
• 1. Use the richness of our data (number and quality of CPPs) to:
• tailor CPPs to our cargo and target of interest; and
• refresh our Intellectual Property estate with a broad 'rule based' claim

1. Orientate our Business Development discussions towards the value of the platform and the programs it is enabling

Phylogica's value proposition

• 1. A 'best in class' Cell Penetrating Peptide (CPP) platform
• 1. That is highly scalable
• 1. At a time when CPPs are reaching the 'tipping point' of clinical validation
• 1. With major technical milestones within reach (therapeutic in vivo read-outs)
• 1. With a multi-year cash runway
• 1. A clear strategy linking technical outcomes to commercial objectives
• 1. An excellent operational team capable of delivering on the strategy

Thank you

For more information contact Dr. Rohan Hockings rohanhockings@phylogica.com

10

Disclaimer

The purpose of the presentation is to provide an update on the business of Phylogica Limited (ASX:PYC) ['Phylogica']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Phylogica and should not be relied upon as an independent source of information. Please contact Phylogica and/or refer to the

The views expressed in this presentation contain information derived from publicly available as to the accuracy, completeness or reliability of the information.

expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in

This presentation should not be relied on as a recommendation or forecast by Phylogica. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.